MedTrace Logo

Efficacy and Safety of HIP1601 Capsule

NCT04080726 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2020-11-30

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with erosive gastroesphageal reflux disease.

Conditions

  • Erosive Gastroesophageal Reflux Disease

Interventions

DRUG

HIP1601

Oral esomeprazole

DRUG

HGP1705

Oral Nexium Tab

DRUG

HIP1601 Placebo

Oral Placebo

DRUG

HGP1705 Placebo

Oral Placebo

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Hunyong Jung, MD, Ph.D. · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-25
Primary Completion
2019-12-03
Completion
2019-12-03

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04080726 on ClinicalTrials.gov